Skip to main content

$0.008 (0%)

High

$0.01

Low

$0.01

Trades

7

Turnover

$2,282

Volume

285,280
30 June 2023 at 3:59pm
Register to track EX1 and receive email alerts.
Subject
EX1 Ann: 2022 AGM Notice of Meeting and Proxy

EX1 Ann: 2022 AGM Letter to Shareholders and Proxy

EX1 Ann: Change in substantial holding

EX1 Ann: Upcoming Webinar

EX1 Ann: Notification regarding unquoted securities - EX1

EX1 Ann: Upcoming Webinar

EX1 Ann: EX1 Building Momentum with in-house Products

EX1 Ann: Investor Presentation

EX1 Ann: Study results indicate exosomes safe for clinical pursuit

EX1 Ann: Date of Annual General Meeting 2022

EX1 Ann: FY2022 Appendix 4E and Annual Report

EX1 Ann: Appendix 4G and Corporate Governance Statement

EX1 Ann: Quarterly Activities Report and Appendix 4C

EX1 Ann: EX1 to receive a further $0.48m in prepaid R&D Tax Incentive

EX1 Ann: EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim

EX1 Ann: Change in substantial holding

EX1 Ann: Business Update

EX1 Ann: Quarterly Activities Report and Appendix 4C

EX1 Ann: Response to ASX Price Query

EX1 Ann: Change in substantial holding

EX1 Ann: Appendix 4D and Half Year Report for period 31 December 2021

EX1 Ann: Response to ASX Query

EX1 Ann: Clarification on Exopharm AIRM MSA Announcement

EX1 Ann: Quarterly Activities Report and Appendix 4C

EX1 Ann: Exopharm and AIRM Sign MSA

EX1 Ann: Change of Director's Interest Notice - ID

EX1 Ann: Change of Director's Interest Notice - JW

EX1 Ann: Notification of cessation of securities - EX1

EX1 Ann: Change in substantial holding

EX1 Ann: Exopharm Gains US Patent for LEAP Technology

EX1 Ann: Results of Annual General Meeting

EX1 Ann: Exopharm to Present at Key Exosome Industry Event

EX1 Ann: Quarterly Activities Report and Appendix 4C

EX1 Ann: 2021 AGM Notice of Meeting and Proxy

EX1 Ann: 2021 AGM Letter to Shareholders and Proxy

EX1 Ann: Appointment of Company Secretary

EX1 Ann: Response to ASX Price Query

EX1 Ann: Exopharm LEAP Technology - Further Step Towards US Patent

EX1 Ann: Exopharm LEAP Technology - Second Commercial Collaboration

EX1 Ann: Change of Director's Interest Notice - EM

EX1 Ann: Change of Director's Interest Notice - JW

EX1 Ann: Change of Director's Interest Notice - ID

EX1 Ann: Cleansing Notice

EX1 Ann: Application for quotation of securities - EX1

EX1 Ann: Date of Annual General Meeting

EX1 Ann: Initial Director's Interest Notice - JK

EX1 Ann: Dr Jenn King joins Exopharm Board

EX1 Ann: Appendix 4G and Corporate Governance Statement

EX1 Ann: FY2021 Appendix 4E and Annual Report

EX1 Ann: Investor Webinar Presentation

Register to track EX1 and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX